Clinical Trials Logo
  1. Home
  2. Autoimmune Encephalitis
  3. NCT03957616

Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis — IPNSAE  

Autoimmune Encephalitis Clinical Trial

Official title:
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018

Clinical Trial Summary

This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03957616
Study type Observational
Source Hospices Civils de Lyon
Contact Géraldine Picard
Phone 4 72 35 58 42
Email geraldine.picard@chu-lyon.fr
Status Not yet recruiting
Phase
Start date May 30, 2019
Completion date July 31, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT05645185 - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Not yet recruiting NCT04106596 - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Completed NCT04708626 - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT05711563 - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT05280600 - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting NCT06173076 - A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT06033846 - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis Phase 2
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Recruiting NCT05177939 - Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis Phase 3
Recruiting NCT06019975 - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed NCT05783947 - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Completed NCT05825690 - BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
Not yet recruiting NCT06079294 - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism N/A
Recruiting NCT03872284 - Neuro-ophthalmology and Autoimmune Encephalitis (NODE)
Terminated NCT03835728 - Efficacy of Ocrelizumab in Autoimmune Encephalitis Phase 2
Active, not recruiting NCT05728931 - New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes